A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 17, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

May 31, 2026

Conditions

Ocular Graft Versus Host Disease

Interventions

DRUG

rhPRG4 450ug/ml

Treatment

DRUG

Vehicle Control

PBS Based Vehicle Control

Trial Locations (3)

Sydney Eye Hospital, Sydney

OTA, Brisbane

Royal Melbourne Hospital, Melbourne

All Listed Sponsors

lead

Lubris Bio Pty Ltd

INDUSTRY